InnovHeart is a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease.
InnovHeart's mission is to bring patients a novel therapeutic system suitable to replace incompetent Mitral Valves based on a safe, effective, and easy-to-use transcatheter technology.
InnovHeart was founed in 2015 by Giovanni Righini. The company is headquartered in Milan, Italy, with an offices in Boston, Masschusetts.
InnovHeart is in late preclinical development of its novel TMVR Saturn Prosthesis, designed to be consistent with the anatomy of the mitral valve and, currently, in development as a Transapical as well as a Transeptal system.
InnovHeart has already demonstrated excellent mid-term (>1 year) results with the trans-apical version. This low profile, adaptive valve design decreases the risk of LVOT obstruction and will be implanted transeptally in FIH in 2022.
InnovHeart is backed by Genextra, Grand Pharmaceutical Group Limited, Panakes Partners, CDP Venture Capital, Indaco Venture Partners, and others. The company raised $55M in Series C round on Jan 27, 2022. This brings InnovHeart's total funding to $102.4M to date.